Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin lesions

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    724 result(s) found for: Skin lesions. Displaying page 1 of 37.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-003326-44 Sponsor Protocol Number: TIRBA-2022-02 Start Date*: 2023-04-11
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Dermatologie und Venerologie
    Full Title: SunDamage: Tirbanibulin 1% Ointment for the treatment of chronically sun-damaged skin on the face
    Medical condition: Subclinical lesions in UV-exposed areas of chronically UV-damaged skin in the face adjacent to lesions caused by actinic keratosis but not obviously affected themselves.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003495-31 Sponsor Protocol Number: CCLL442X2201 Start Date*: 2017-12-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients w...
    Medical condition: Cutaneous Squamous Cell Carcinoma in situ (SCCis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003189-15 Sponsor Protocol Number: S61472 Start Date*: 2018-10-05
    Sponsor Name:University Hospitals Leuven
    Full Title: STRAUSS: responSe To ustekinumab foR Anti-tnf IndUced pSoriasiform Skin lesions
    Medical condition: Anti-TNF induced psoriasiform skin lesions in patients with inflammatory bowel diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005624-13 Sponsor Protocol Number: 509002.01.403 Start Date*: 2006-03-15
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Investigation on treatment effect and safety of Hametum® Wund- und Heilsalbe in patients with drug induced skin symptoms. An open phase IV trial [Untersuchung zu Behandlungseffekt und Verträglichk...
    Medical condition: Patients with drug induced skin symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007055-28 Sponsor Protocol Number: P-080623-01 Start Date*: 2009-06-04
    Sponsor Name:Ferrer International, SA
    Full Title: GF-001001-00 cream. A multicentre, randomised, double-blind, parallel, placebo-controlled phase II study to assess the efficacy and safety of 3 different doses of GF-001001-00 cream versus placebo...
    Medical condition: Secondarily-infected traumatic lesions
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040872 Skin infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003374-10 Sponsor Protocol Number: TOC106489 Start Date*: 2007-08-03
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated...
    Medical condition: Uncomplicated skin and skin structure infections
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001722-21 Sponsor Protocol Number: D533AC00001 Start Date*: 2022-03-08
    Sponsor Name:AstraZeneca AB
    Full Title: MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance ...
    Medical condition: Unresectable or Advanced Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002285-12 Sponsor Protocol Number: OJ-KDC01 Start Date*: 2019-12-02
    Sponsor Name:LABORATORIO OJER PHARMA, S.L.
    Full Title: An exploratory, multicenter, randomized, open-label with blind evaluation, active-controlled study to evaluate the safety and efficacy of Keramod (imiquimod 50 mg/g, Gel) compared with Aldara (imi...
    Medical condition: ACTINIC QUERATOSIS, also known as solar keratosis, is a skin disease caused by chronic exposure to sunlight. It appears as scaly lesions on the skin as a result of an abnormal growth of the cells i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000314-15 Sponsor Protocol Number: LPS15991 Start Date*: 2021-08-17
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Open label exploratory study to evaluate the effect of dupilumab on skin barrier function in patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001518-40 Sponsor Protocol Number: LPS16764 Start Date*: 2020-12-15
    Sponsor Name:Sanofi Aventis Recherche & Developpement
    Full Title: Open-label exploratory study to evaluate the effect of dupilumab on skin barrier function in pediatric patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-006738-33 Sponsor Protocol Number: CL-1205 Start Date*: 2008-03-14
    Sponsor Name:NatImmune A/S
    Full Title: bLAC - A phase II double-blind, placebo controlled, clinical proof of concept trial of the efficacy of 8 weeks treatment of cutaneous warts with bLAC in immune suppressed, kidney transplanted patients
    Medical condition: Cutaneous wart lesions on hands and/or feet at immune suppressed, kidney transplanted patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010115 Common warts LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005121-13 Sponsor Protocol Number: Daylight_01 Start Date*: 2015-07-22
    Sponsor Name:University Hospital Regensburg
    Full Title: Prospective, randomized, controlled, multicenter, two-armed, study comparing daylight photodynamic therapy using MAL with cryosurgery for the treatment and prophylaxis of actinic keratoses in photo...
    Medical condition: Actinic keratoses and photoaged skin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003241-42 Sponsor Protocol Number: ALA-BCC-CT008 Start Date*: 2013-12-23
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcin...
    Medical condition: Basal cell carcinoma (BCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006191-30 Sponsor Protocol Number: IDI-ONC-3-20080901 Start Date*: 2008-12-20
    Sponsor Name:ISTITUTO DERMOPATICO IMMACOLATA
    Full Title: Biweekly Bevacizumab and weekly Carboplatin and Paclitaxel as II line therapy in advanced Malignant Melanoma patients: a phase II study
    Medical condition: patients with histologically confirmed progressive metastastic melanoma progressed after first line chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    9.1 10027480 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001708-12 Sponsor Protocol Number: 4518000 Start Date*: 2018-12-19
    Sponsor Name:Alcedis GmbH
    Full Title: A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cu...
    Medical condition: Unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005627-17 Sponsor Protocol Number: TR03 Start Date*: 2015-12-01
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000294-29 Sponsor Protocol Number: PLD-Caps_Protocol-V1.0 Start Date*: 2007-04-20
    Sponsor Name:Department of Dermatology, medical University of Graz
    Full Title: Die Bedeutung des sensorischen Nervensystems der Haut bei polymorpher Lichtdermatose English title: The role of the cutaneous sensory nervous system in polymorphic light eruption (PLE)
    Medical condition: Polymorphic light eruption
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004314-34 Sponsor Protocol Number: CaEP-R Start Date*: 2019-12-05
    Sponsor Name:Julie Gehl
    Full Title: PHASE II INVESTIGATION OF CALCIUM ELECTROPORATION AS A TREATMENT FOR CUTANEOUS AND SUBCUTANEOUS MALIGNANT TUMOURS
    Medical condition: Cutaneous or subcutaneous malignant tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026693 Malignant skin neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-006372-17 Sponsor Protocol Number: Field-Cancerization Start Date*: 2022-02-15
    Sponsor Name:Muehlenkreiskliniken AoeR
    Full Title: Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced f...
    Medical condition: advanced or metastatic cutaneous squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085908 Cutaneous squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003802-14 Sponsor Protocol Number: CRC-PSO-SKINPEN-A-27 Start Date*: 2016-11-25
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 14:22:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA